About Karen Hadley

This author has not yet filled in any details.
So far Karen Hadley has created 30 blog entries.

BOOK REVIEW: American Cartel: Inside the Battle to Bring Down the Opioid Industry

By |2022-08-22T13:28:05-04:00August 30th, 2022|CSDAP Original Content, News, Policy Makers|

Writer Karen Hadley contributed a review this book by Scott Higham and Sari Horwitz. The first half of American Cartel tells the story of how the DEA was forced to change by The Alliance, a cartel of drug manufacturers who had no intention of letting the DEA change anything about their business model. And Joe Rannazzisi stood in the way of their being able to do business exactly as they chose. So he had to go. And the only way to accomplish that goal was through changing the law in America that enabled him to do his job. So that’s exactly what they did.

The Lancet-Stanford Commission Recommendations for Resolving Opioid Deaths in North America

By |2022-04-01T13:44:28-04:00March 4th, 2022|CSDAP Original Content, Medical Model, Pathways to Recovery, Research, Studies and Reports|

In 2020, a special commission was convened to review causes and solutions for the increasing number of opioid deaths in North America. In February 2022, the Commission released its report. If the Commission proposes any effective methods of stopping this runaway freight train, those suggestions should be immediately and seriously considered.

A Phase 2a Study of Antibody for Methamphetamine Outpatient Therapy

By |2022-05-04T10:37:14-04:00March 4th, 2022|Medical Model, Pathways to Recovery, Pharma, Policy Makers, Service Providers, Treatment Drugs (non-Suboxone)|

The US FDA has not approved any medications for the treatment of methamphetamine (METH) use disorders. Currently, cognitive-behavioral and contingency-management interventions are the most effective treatments. IXT-m200, a monoclonal antibody that specifically binds METH in the blood, is being developed as a pharmacological treatment for use in conjunction with behavior therapies. Based on nonclinical studies, IXT-m200 is expected to alter METH pharmacokinetics in human subjects resulting in reduced or blocked METH subjective effects that reinforce METH use.

Faith-Based and Community Organizations and Addiction Recovery

By |2022-03-25T13:08:04-04:00January 25th, 2022|CSDAP Original Content, Pathways to Recovery|

Two decades ago, President George W. Bush established the White House Faith-Based and Community Initiative to encourage and coordinate community activities in providing social services. This initiative was renewed by Presidents Obama and Biden. But these renewals exclude a focus of faith-based and community groups on problems like substance abuse and addiction. Does the rise of medication-assisted treatment play a role in this exclusion?

The Plusses and Minuses of MAT Drugs

By |2022-04-07T17:23:55-04:00January 24th, 2022|CSDAP Original Content, Medical Model, Policy Makers, Service Providers, Suboxone (Buprenorphine), Treatment Drugs (non-Suboxone)|

Methadone and various formulations containing buprenorphine are treatment drugs used in medication-assisted treatment, usually referred to as MAT. These are the MAT drugs approved for treatment of opioid addiction (opioid painkillers, heroin, fentanyl). We will take a look at the minus side as well as the plus side of these opioid addition treatment drugs. Treatment with MAT drugs can be right for some people. But anyone choosing this treatment so they can leave addiction behind should be prepared for the minus side of MAT.

Is an Opioid Distributor Still Seeking to Profit from the Opioid Epidemic?

By |2022-03-25T13:10:59-04:00January 19th, 2022|CSDAP Original Content, Medical Model, Pharma, Suboxone (Buprenorphine), Treatment Drugs (non-Suboxone)|

In 2018, McKesson committed the astronomical sum of $100 million to support a new non-profit group, the FORE Foundation. Is there any reason, really, to think twice about this collaboration between McKesson and the FORE Foundation? The answer might be "yes." This type of action was one of the tactics used by Purdue Pharma to smooth the path to increased opioid prescribing—getting a non-profit to spend your money making increased use of your products possible. In the end, even this move could be all about profits.

This again? “LSD helps to treat alcoholism”

By |2022-04-07T17:42:55-04:00January 19th, 2022|Research, Studies and Reports, Treatment Drugs (non-Suboxone)|

The powerful hallucinogen LSD (lysergic acid diethylamide) has potential as a treatment for alcoholism, according to a retrospective analysis of studies published in the late 1960s and early 1970s… Psychedelics were promoted by psychiatrists in the 1950s as having a range of medical uses — to treat conditions such as schizophrenia, for example — before political pressures in the United States and elsewhere largely ended the work.

Decriminalization — Harm Reduction — Medication — Have We Forgotten About Rehabilitation?

By |2022-02-10T21:49:53-05:00January 18th, 2022|Medical Model, Pathways to Recovery, Suboxone (Buprenorphine)|

A stunning report this week that an estimated 93,000 people died of drug overdoses in 2020 has renewed attention on the nation’s other epidemic: The drug crisis that the government, health-care workers and street-level activists have been battling unsuccessfully for more than two decades... A wide spectrum of changes has been offered by government, academic and think tank researchers, criminal justice experts and health-care workers, and lay people to try to help the nation’s more than 8.1 million people with substance use disorders. Solutions range from completely decriminalizing the consumption of drugs, as Portugal did in 2001, to overturning the way the health-care system treats users.

Serotonin Syndrome “Strikingly High” in Patients Receiving Buprenorphine

By |2022-04-07T17:44:00-04:00January 17th, 2022|Research, Studies and Reports, Service Providers, Suboxone (Buprenorphine)|

The prevalence of serotonin syndrome, which, at its most severe, is a potentially life-threatening drug reaction that increases serotonin levels, is strikingly high in patients receiving buprenorphine (Suboxone, Reckitt Benckiser) on an outpatient basis for opioid addiction, a single-center study shows. "The Suboxone clinic presented so many cases, so many women having ankle clonus and agitation and tremor, I thought that this was worth reporting. In fact, 43% of our patients showed some degree of serotonin syndrome. Yet, many mild and moderate cases of serotonin syndrome go unrecognized," lead researcher Shawn Cassady, MD, from the First Step clinic, in Cockeysville, Maryland, told Medscape Medical News.

SAMHSA Offers Sound Guidelines for Well-Rounded Recovery

By |2022-04-07T17:44:31-04:00January 14th, 2022|CSDAP Original Content, Pathways to Recovery|

Navigating the many choices of recovery programs can be baffling until you grasp the Four Dimensions of Recovery outlined by the Substance Abuse and Mental Health Services Administration. These dimensions provide insight into the qualities of a rehabilitation program that has a chance of true and lasting success.

Go to Top